Meet ASX listed companies, learn what makes their business compelling, ask their CEOs and executives the questions you want, to get the leading edge, make better-informed decisions and learn about market opportunities.The Finance Network and its event partner, preeminent wealth manager Shaw and Partners, run regular Investor Events that unite companies, investors and stockbrokers.

Register now and secure your virtual seat.

Wednesday, 2 December 2020

Online Live Streaming Event
5 companies x 15 mins presentations
Starts at 12.30 PM (Sydney, GMT+10:00)
Free for investors, brokers and fund managers

  >> Assistance with Joining our Live Events
>> How to Customise the Webex Interface (1min)

Market Update 

Event Partner


Martin Crabb
(Chief Investment Officer), Shaw and Partners Limited

Covering the current state of equity markets, COVID-19 outlook and portfolio positioning (5mins).
 

Presenting Companies 

Paul Niardone (Managing Director)The Agency Group Australia (ASX:AU1)

The Agency Group Australia is one of Australia's fastest growing integrated real estate services companies. In over 2 years since listing on the ASX, the Company has established a national presence across key metropolitan markets in Australia led by an industry-leading management team. The Agency Group today has built a fully serviced real estate firm creating an organisation designed to scale.

The Company dual property sales business model, offering both premium full service and independent brand offering underpins its strategy to reach leadership across Australia in terms of agent market share.



Geoffrey Kempler (CEO & Chairman)Alterity Therapeutics (ASX:ATH)

Alterity Therapeutics exists to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.

Alterity Therapeutics was incorporated in Melbourne, Australia in 1997 as Prana Biotechnology and has offices in Melbourne, Australia, and San Francisco, USA. The Company listed on the Australian Securities Exchange in 2000 and listed on the NASDAQ in 2002.



Joe Walsh (Managing Director)Lepidico (ASX: LPD)

Lepidico is a global lithium exploration and development company with offices in Perth and Toronto. Differentiated by its 100% owned clean-tech L-Max®process technology that extracts lithium and recovers valuable by-products from less contested lithium-mica and phosphate minerals. Lepidico’s strategic objective is to become a vertically integrated business, from mine to production of battery grade lithium chemical.

In a relatively short period of time, Lepidico has established a global footprint in lithium via projects, joint ventures and alliances in Australia, Canada and Portugal. The Company’s shares are traded on the Australian Securities Exchange (ASX) and also on German stock exchanges.



Dr Tony Keating (MD & CEO)ResApp Health (ASX:RAP)

ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease.

We are creating easy to use, affordable, clinically-validated and regulatory-cleared diagnostic tools that only require a smartphone. Our solutions are designed to be easily integrated into existing telehealth solutions and we are also working on apps to provide respiratory disease diagnosis and management directly to consumers and healthcare providers. 



James McBrayer (CEO & MD)Cyclopharm (ASX:CYC)

Cyclopharm is a company in the diagnostic imaging field specialising in lung health. We achieve this positioning through our proprietary medical device and pharmaceutical products under the name of Technegas™ which has become the industry gold-standard in diagnostic functional lung imaging technology. Cyclopharm is an established Australian radiopharmaceutical company servicing the global medical community since 1986.

Cyclopharm is a company in the diagnostic imaging field specialising in lung health. We achieve this positioning through our proprietary medical device and pharmaceutical products under the name of Technegas™ which has become the industry gold-standard in diagnostic functional lung imaging technology.

Future Events

23 February  |  23 March   |  20 April 2021
For listed companies, please contact:

Peter Gillespie - Mobile: 0413 807 797  Email: peter@fnn.com.au
Sasho Sokolovski - Mobile: 0409 965 427  Email: sasho@fnn.com.au

If you would like to have further information on any of FNN's events, please contact +61 2 8294 4302
 

Event Sponsors